Literature DB >> 25555473

Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers.

Susan B Brown1, Susan E Hankinson2.   

Abstract

Data from laboratory and epidemiologic studies support a relationship between endogenous hormones and the increased risk of several female cancers. In epidemiologic studies, consistent associations have been observed between risk of breast, ovarian and endometrial cancers and reproductive and hormonal risk factors such as high postmenopausal body mass index (BMI) and postmenopausal hormone use, which suggest the importance of endogenous hormones in the etiology of these diseases. The relationship between circulating estrogen levels in postmenopausal women and the risk of breast cancer is well established, with an approximately 2-fold higher risk among women in the top 20-25% (versus bottom 20-25%) of levels. However, data evaluating the relationship between endogenous estrogens and premenopausal breast cancer risk are more limited and less consistent. Two studies to date have evaluated the relationship between circulating estrogens and breast cancer risk by menstrual cycle phase at blood collection and only one study has examined this relationship by menopausal status at diagnosis. Three prospective studies have evaluated circulating estrogen levels and endometrial cancer risk in postmenopausal women, with consistent strong positive associations reported (with relative risks of 2-4 comparing high versus low hormone levels), while this relationship has not been studied in premenopausal women. Compared to breast and endometrial cancers, reproductive and hormonal characteristics such as postmenopausal hormone use are generally weaker and less consistent risk factors for ovarian cancer, and the only small prospective study conducted to date indicated a non-significant positive relationship between circulating estrogen levels and ovarian cancer risk. In this review, we summarize current evidence and identify key areas to be addressed in future epidemiologic studies of endogenous estrogens and the risk of breast, endometrial, and ovarian cancers.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast cancer; Endogenous hormones; Endometrial cancer; Estrogens; Ovarian cancer

Mesh:

Substances:

Year:  2014        PMID: 25555473     DOI: 10.1016/j.steroids.2014.12.013

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  57 in total

1.  Comparability of serum, plasma, and urinary estrogen and estrogen metabolite measurements by sex and menopausal status.

Authors:  Sally B Coburn; Frank Z Stanczyk; Roni T Falk; Katherine A McGlynn; Louise A Brinton; Joshua Sampson; Gary Bradwin; Xia Xu; Britton Trabert
Journal:  Cancer Causes Control       Date:  2018-12-01       Impact factor: 2.506

2.  Estrogen and insulin synergistically promote type 1 endometrial cancer progression.

Authors:  Wenyan Tian; Fei Teng; Jing Zhao; Jinping Gao; Chao Gao; Dandan Sun; Guoyan Liu; Yanfang Zhang; Shizhu Yu; Wei Zhang; Yingmei Wang; Fengxia Xue
Journal:  Cancer Biol Ther       Date:  2017-11-27       Impact factor: 4.742

Review 3.  Iron overload and altered iron metabolism in ovarian cancer.

Authors:  Stephanie Rockfield; Joseph Raffel; Radhe Mehta; Nabila Rehman; Meera Nanjundan
Journal:  Biol Chem       Date:  2017-08-28       Impact factor: 3.915

4.  Elevated expression of G protein-coupled receptor 30 (GPR30) is associated with poor prognosis in patients with uterine cervical adenocarcinoma.

Authors:  Yoshihiko Ino; Taishi Akimoto; Akira Takasawa; Kumi Takasawa; Tomoyuki Aoyama; Asako Ueda; Misaki Ota; Kazufumi Magara; Yohei Tagami; Masaki Murata; Tadashi Hasegawa; Tsuyoshi Saito; Norimasa Sawada; Makoto Osanai
Journal:  Histol Histopathol       Date:  2019-09-04       Impact factor: 2.303

5.  Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.

Authors:  Jacqueline M Dempsey; Kelley M Kidwell; Christina L Gersch; Andrea M Pesch; Zeruesenay Desta; Anna Maria Storniolo; Vered Stearns; Todd C Skaar; Daniel F Hayes; N Lynn Henry; James M Rae; Daniel L Hertz
Journal:  Pharmacogenomics       Date:  2019-06       Impact factor: 2.533

6.  Severe acne and risk of breast cancer.

Authors:  John D Murphy; Dale Sandler; Alexandra J White; Katie M O'Brien
Journal:  Breast Cancer Res Treat       Date:  2019-06-05       Impact factor: 4.872

Review 7.  L-Type Calcium Channels Modulation by Estradiol.

Authors:  Nelson E Vega-Vela; Daniel Osorio; Marco Avila-Rodriguez; Janneth Gonzalez; Luis Miguel García-Segura; Valentina Echeverria; George E Barreto
Journal:  Mol Neurobiol       Date:  2016-08-15       Impact factor: 5.590

8.  Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women.

Authors:  Louise A Brinton; Britton Trabert; Garnet L Anderson; Roni T Falk; Ashley S Felix; Barbara J Fuhrman; Margery L Gass; Lewis H Kuller; Ruth M Pfeiffer; Thomas E Rohan; Howard D Strickler; Xia Xu; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-12       Impact factor: 4.254

Review 9.  Diabetes mellitus and metformin in hepatocellular carcinoma.

Authors:  Koji Fujita; Hisakazu Iwama; Hisaaki Miyoshi; Joji Tani; Kyoko Oura; Tomoko Tadokoro; Teppei Sakamoto; Takako Nomura; Asahiro Morishita; Hirohito Yoneyama; Tsutomu Masaki
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

10.  Assay reproducibility of serum androgen measurements using liquid chromatography-tandem mass spectrometry.

Authors:  Britton Trabert; Xia Xu; Roni T Falk; Chantal Guillemette; Frank Z Stanczyk; Katherine A McGlynn
Journal:  J Steroid Biochem Mol Biol       Date:  2015-09-28       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.